Fred J. Kudrik

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

Robert Z. Orlowski, Peter M. Voorhees, Reynaldo Garcia et al. · Blood · 2004 · 319 citations

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma

Al B. Benson, Zev A. Wainberg, J. Randolph Hecht et al. · The Oncologist · 2017 · 167 citations · Full text

Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease

Mark A. Socinski, Frederic J. Kaye, David R. Spigel et al. · Clinical Lung Cancer · 2016 · 77 citations · Full text

A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States

Lawrence E. Flaherty, Omid Hamid, Gerald P. Linette et al. · The Cancer Journal · 2014 · 52 citations · Full text

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy

Miranda A. Moore, Sanjeev Gill, Timothy R. Asmis et al. · Annals of Oncology · 2016 · 35 citations · Full text

Gastrointestinal Oncology, Medicine, Pharmacology +10